Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1998 2
2000 2
2001 4
2002 3
2004 1
2006 1
2007 1
2010 1
2011 1
2012 6
2013 1
2014 9
2015 12
2016 22
2017 4
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

70 results
Results by year
Filters applied: . Clear all
Page 1
RRx-001, A novel dinitroazetidine radiosensitizer.
Oronsky B, Scicinski J, Ning S, Peehl D, Oronsky A, Cabrales P, Bednarski M, Knox S. Oronsky B, et al. Among authors: scicinski j. Invest New Drugs. 2016 Jun;34(3):371-7. doi: 10.1007/s10637-016-0326-y. Epub 2016 Feb 3. Invest New Drugs. 2016. PMID: 26841903 Free PMC article. Review.
Episensitization: Defying Time's Arrow.
Oronsky BT, Oronsky AL, Lybeck M, Oronsky NC, Scicinski JJ, Carter C, Day RM, Rodriguez Orengo JF, Rodriguez-Torres M, Fanger GF, Reid TR. Oronsky BT, et al. Among authors: scicinski jj. Front Oncol. 2015 Jun 11;5:134. doi: 10.3389/fonc.2015.00134. eCollection 2015. Front Oncol. 2015. PMID: 26125013 Free PMC article. Review.
The war on cancer: a military perspective.
Oronsky B, Carter CA, Mackie V, Scicinski J, Oronsky A, Oronsky N, Caroen S, Parker C, Lybeck M, Reid T. Oronsky B, et al. Among authors: scicinski j. Front Oncol. 2015 Jan 26;4:387. doi: 10.3389/fonc.2014.00387. eCollection 2014. Front Oncol. 2015. PMID: 25674537 Free PMC article. Review.
Rockets, radiosensitizers, and RRx-001: an origin story part I.
Oronsky B, Scicinski J, Ning S, Peehl D, Oronsky A, Cabrales P, Bednarski M, Knox S. Oronsky B, et al. Among authors: scicinski j. Discov Med. 2016 Mar;21(115):173-80. Discov Med. 2016. PMID: 27115167 Free article. Review.
Going viral: a review of replication-selective oncolytic adenoviruses.
Larson C, Oronsky B, Scicinski J, Fanger GR, Stirn M, Oronsky A, Reid TR. Larson C, et al. Among authors: scicinski j. Oncotarget. 2015 Aug 21;6(24):19976-89. doi: 10.18632/oncotarget.5116. Oncotarget. 2015. PMID: 26280277 Free PMC article. Review.
No patient left behind: The promise of immune priming with epigenetic agents.
Carter CA, Oronsky BT, Roswarski J, Oronsky AL, Oronsky N, Scicinski J, Lybeck H, Kim MM, Lybeck M, Reid TR. Carter CA, et al. Among authors: scicinski j. Oncoimmunology. 2017 Aug 30;6(10):e1315486. doi: 10.1080/2162402X.2017.1315486. eCollection 2017. Oncoimmunology. 2017. PMID: 29123948 Free PMC article. Review.
Turning on the Radio: Epigenetic Inhibitors as Potential Radiopriming Agents.
Oronsky B, Scicinski J, Kim MM, Cabrales P, Salacz ME, Carter CA, Oronsky N, Lybeck H, Lybeck M, Larson C, Reid TR, Oronsky A. Oronsky B, et al. Among authors: scicinski j. Biomolecules. 2016 Jul 4;6(3):32. doi: 10.3390/biom6030032. Biomolecules. 2016. PMID: 27384589 Free PMC article. Review.
Follow the ATP: tumor energy production: a perspective.
Oronsky BT, Oronsky N, Fanger GR, Parker CW, Caroen SZ, Lybeck M, Scicinski JJ. Oronsky BT, et al. Among authors: scicinski jj. Anticancer Agents Med Chem. 2014;14(9):1187-98. doi: 10.2174/1871520614666140804224637. Anticancer Agents Med Chem. 2014. PMID: 25102360 Review.
Rewriting the epigenetic code for tumor resensitization: a review.
Oronsky B, Oronsky N, Scicinski J, Fanger G, Lybeck M, Reid T. Oronsky B, et al. Among authors: scicinski j. Transl Oncol. 2014 Oct 24;7(5):626-31. doi: 10.1016/j.tranon.2014.08.003. eCollection 2014 Oct. Transl Oncol. 2014. PMID: 25389457 Free PMC article. Review.
RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials.
Oronsky B, Paulmurugan R, Foygel K, Scicinski J, Knox SJ, Peehl D, Zhao H, Ning S, Cabrales P, Summers TA Jr, Reid TR, Fitch WL, Kim MM, Trepel JB, Lee MJ, Kesari S, Abrouk ND, Day RM, Oronsky A, Ray CM, Carter CA. Oronsky B, et al. Among authors: scicinski j. Expert Opin Investig Drugs. 2017 Jan;26(1):109-119. doi: 10.1080/13543784.2017.1268600. Expert Opin Investig Drugs. 2017. PMID: 27935336 Free article. Review.
70 results